14-3-3η Protein: Extracellular 14-3-3η Perpetuates Disease
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signalling pathways that lead to the up-regulation of inflammation and joint damage factors involved in RA pathogenesis. The 14-3-3η blood test is clinically available as a diagnostic test whereby a positive result indicates a 5 to 50 times greater likelihood of having RA and informs joint damage prognosis and disease monitoring. 14-3-3η is used alone, or in combination with other serological tests and clinical assessment to support RA patient management.
- 14-3-3η is a Novel Mediator Associated with the Pathogenesis of Rheumatoid Arthritis and Joint Damage
- 14-3-3η Promotes Invadosome Formation via the FOXO3–Snail Axis in Rheumatoid Arthritis Fibroblast-like Synoviocytes
- Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages
- Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
- 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
- The Diagnostic Value of 14-3-3η Protein Levels in Patients with Rheumatoid Arthritis
- Serum 14-3-3η Protein is Associated with Clinical and Serologic Features of Sjögren’s Syndrome in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Analysis
- Evaluation of Serum Protein 14-3-3 Eta as a Novel Biomarker for Juvenile Idiopathic Arthritis
- Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
- Serum Levels of 14-3-3η Protein Supplement C-reactive Protein and Rheumatoid Arthritis-Associated Antibodies to Predict Clinical and Radiographic Outcomes in a Prospective Cohort of Patients with Recent-Onset Inflammatory Polyarthritis
- Impending Radiographic Erosive Progression Over the Following Year in a Cohort of Consecutive Patients with Inflammatory Polyarthritis: Prediction by Serum Biomarkers
- Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial
- Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
- Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib
- Correlation of Plasma 14-3-3η Levels with Disease Activity Measures in Methotrexate-Naïve RA Patients Treated with Upadacitinib Monotherapy in the Select-Early Phase 3 Study
In the US, the 14-3-3η blood test is available for clinical use through Quest Diagnostics, and LabCorp as an RA diagnostic panel including RF and anti-CCP and as a standalone test to facilitate 14-3-3η serial measurements for ongoing patient management.
Comments are closed.